# Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer

> **NCT01282333** · PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 44 (actual)

## Conditions studied

- Advanced Adult Primary Liver Cancer
- Localized Unresectable Adult Primary Liver Cancer
- Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
- Regional Transitional Cell Cancer of the Renal Pelvis and Ureter
- Stage III Bladder Cancer
- Stage III Pancreatic Cancer
- Stage IIIA Non-small Cell Lung Cancer
- Stage IIIB Non-small Cell Lung Cancer
- Stage IV Bladder Cancer
- Stage IV Non-small Cell Lung Cancer
- Stage IV Pancreatic Cancer
- Transitional Cell Carcinoma of the Bladder
- Unresectable Extrahepatic Bile Duct Cancer
- Unresectable Gallbladder Cancer

## Interventions

- **DRUG:** gemcitabine hydrochloride
- **DRUG:** veliparib
- **OTHER:** diagnostic laboratory biomarker analysis
- **OTHER:** pharmacological study
- **DRUG:** cisplatin

## Key facts

- **NCT ID:** NCT01282333
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-01
- **Primary completion:** 2013-02
- **Final completion:** —
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2013-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01282333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01282333, "Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01282333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*